StockNews.AI
IONS
StockNews.AI
195 days

Ionis to hold fourth quarter and full year 2024 financial results webcast

1. Ionis will webcast 2024 financial results on February 19. 2. The company has six marketed medicines and a strong pipeline. 3. Ionis is a leader in RNA-targeted medicine innovation. 4. They focus on neurology, cardiology, and rare diseases. 5. They are advancing new gene editing approaches.

Earnings
+3.1%Current Return
VS
+0.61%S&P 500
$31.6402/05 07:28 AM EDTEvent Start
$32.6202/06 02:16 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Neutral?

The webcast could reveal important financial data influencing IONS stock. However, the lack of immediate catalysts limits price movement.

How important is it?

Earnings announcements typically influence stock price. IONS' ongoing research and development may also contribute to future price movements.

Why Short Term?

Immediate reaction may occur post-webcast based on results. Market responds quickly to quarterly earnings disclosures.

Related Companies

IONSMRNAAVRO
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, February 19th at 11:30 a.m. Eastern Time to discuss its fourth quarter and full year 2024 financial results. The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address. About Ionis Pharmaceuticals, Inc. For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has six marketed medicines and a leading pipeline in innovative late- and mid-stage pipeline across our focus areas of neurology, cardiology and rare diseases. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter) and LinkedIn.

Related News